MedTrace Logo

CHI-907 CBD Extract and Experiences of Test Anxiety

NCT04269252 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-06-04

No results posted yet for this study

Summary

This is a randomized, placebo-controlled study examining the effects of CHI-907 on test anxiety specifically, and state anxiety more broadly.

Conditions

Interventions

OTHER

CHI-907

CHI-907 is a high CBD extract.

OTHER

CHI-804

CHI-804 is the placebo formulation.

Sponsors & Collaborators

  • James Madison University

    collaborator OTHER

  • Canopy Growth Corporation

    lead INDUSTRY

Principal Investigators

  • Mark Ware, MD · Canopy Growth Corporation

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04269252 on ClinicalTrials.gov